| Primary information |
|---|
| ID | antitb_1994, |
| Name | 26352292 |
| N-Terminal modification | VpAmp2.0 |
| C-Terminal Modification | FWGFLGKLAMKAVPSLIGGNKSSSK |
| Chemical Modification | Free |
| Linear/Cyclic | Free |
| Length | None |
| Chirality | Linear |
| Nature | 25 |
| Source | L |
| Origin | Cationic |
| Species | Synthetic |
| Inhibition Concentration | Mycobacterium tuberculosis |
| In Vitro/ In vivo | Mycobacterium tuberculosis H37Rv |
| Cell Line | MIC= 21.4 ± 7.5 µM |
| Inhibition Concentration | In vitro |
| Sequence | 2015 |
| Cytotoxicity | NA |
| In vivo Model | NA |
| Lethal Dose | NA |
| Immune Responce | NA |
| Mechanism of Action | NA |
| Target | NA |
| Combination Therapy | NA |
| Other activities | Cell wall |
| PMID | NA |
| Year of Publication | Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, Streptococcus agalactiae |
Tertiary Structure
(Technique) | Not Predicted), |
| Primary information |
|---|
| ID | antitb_1995, |
| Name | 26352292 |
| N-Terminal modification | VpAmp2.0 |
| C-Terminal Modification | FWGFLGKLAMKAVPSLIGGNKSSSK |
| Chemical Modification | Free |
| Linear/Cyclic | Free |
| Length | None |
| Chirality | Linear |
| Nature | 25 |
| Source | L |
| Origin | Cationic |
| Species | Synthetic |
| Inhibition Concentration | Mycobacterium tuberculosis |
| In Vitro/ In vivo | Mycobacterium tuberculosis MDR |
| Cell Line | MIC= 30.5 ± 9.5 µM |
| Inhibition Concentration | In vitro |
| Sequence | 2015 |
| Cytotoxicity | NA |
| In vivo Model | NA |
| Lethal Dose | NA |
| Immune Responce | NA |
| Mechanism of Action | NA |
| Target | NA |
| Combination Therapy | NA |
| Other activities | Cell wall |
| PMID | NA |
| Year of Publication | Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, Streptococcus agalactiae |
Tertiary Structure
(Technique) | Not Predicted), |